European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading

MT Newswires Live07-20 23:13

European equities traded in the US as American depositary receipts started the week lower late Monday morning, falling 0.61% to 1,891.41 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Grifols (GRFS) and semiconductor company Sequans Communications (SQNS), which rose 3% and 2.4% respectively. They were followed by medical device maker EDAP TMS (FOCL) and brewing company Anheuser-Busch InBev (BUD), which were up 1.1% and 1% respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and software company SAP (SAP), which fell 3.7% and 2.6% respectively. They were followed by pharmaceutical company Sanofi (SNY) and internet ad firm Criteo (CRTO), which were down 1.8% and 1.3% respectively.

The gainers from the UK were led by biopharmaceutical company Akari Therapeutics (AKTX) and alcoholic beverage company Diageo (DEO), which increased 5.2% and 0.8% respectively. They were followed by insurance company Prudential (PUK) and communications company WPP (WPP), which advanced 0.7% and 0.6% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Trinity Biotech (TRIB), which lost 4.3% and 4.2% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and software company Endava (DAVA), which were off 2.7% each.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment